Adverum Biotechnologies Inc ADVM.OQ ADVM.O is expected to show a fall in quarterly revenue when it reports results on November 5 (estimated) for the period ending September 30 2025
LSEG's mean analyst estimate for Adverum Biotechnologies Inc is for a loss of $1.58 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Adverum Biotechnologies Inc is $5.00, about 14% above its last closing price of $4.30
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2025 | -2.25 | -2.25 | -2.34 | Missed | -4.2 |
Mar. 31 2025 | -1.91 | -1.81 | -2.25 | Missed | -24 |
Dec. 31 2024 | -1.36 | -1.96 | Missed | -44.2 | |
Sep. 30 2024 | -1.29 | -1.31 | -1.30 | Beat | 0.5 |
Jun. 30 2024 | -1.44 | -1.47 | -0.89 | Beat | 39.4 |
Mar. 31 2024 | -1.55 | -1.40 | -1.50 | Missed | -6.8 |
Dec. 31 2023 | -3.35 | -3.37 | -2.30 | Beat | 31.7 |
Sep. 30 2023 | -3.06 | -3.15 | -3.30 | Missed | -4.7 |
This summary was machine generated November 3 at 11:47 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments